[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 6, Number 2 (Int J Mol Cell Med 2017) ::
Int J Mol Cell Med 2017, 6(2): 0-0 Back to browse issues page
Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia
Amr Rafat Elhamamsy *1, Muhammad Suleiman El Sharkawy2, Ahmed Farouk Zanaty2, Mohammed Ahmed Mahrous3, Ahmed Ezzat Mohamed2, Eslam Ahmed Abushaaban2
1- Department of Clinical Pharmacy, School of Pharmacy, Tanta University, 31516 Tanta, Egypt., Department of Clinical Pharmacy, School of Pharmacy, Tanta University, 31516 Tanta, Egypt. , amr35354@pharm.tanta.edu.eg
2- Department of Clinical Pharmacy, Tanta Cancer Center, 31527 Tanta, Egypt., Department of Clinical Pharmacy, Tanta Cancer Center, 31527 Tanta, Egypt.
3- Department of Clinical Pharmacy, School of Pharmacy, Tanta University, 31516 Tanta, Egypt., Department of Clinical Pharmacy, School of Pharmacy, Tanta University, 31516 Tanta, Egypt.
Abstract:   (364 Views)

MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional gene expression regulators. The expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to assess tumor initiation, progression and response to treatment in cancer patients. Recent Studies opened the way for the use of circulating miRNAs as non-invasive diagnosis and prognosis of Acute Myeloid Leukemia (AML). The aim of this study was to identify plasma miR-92a, miR-143 and miR-342 expression signatures in AML patients to introduce new markers for establishing AML diagnosis and prognosis. Blood samples were collected from 65 AML patients and 50 controls. The expression of three target miRNAs (miR-92a, miR-143 and miR-342) was measured using quantitative real-time PCR method. Plasma levels of miR-92a, miR-143 and miR-342 were significantly lower in AML patients in comparison with control group. Receiver operator characteristic (ROC) analysis revealed that the sensitivity and specificity values of miR-92a were 81.5% and 94%, respectively, with a cut-off value of 0.704. The sensitivity and specificity values of miR-143 were 87.7% and 80%, respectively, with a cut-off value of 0.65. The sensitivity and specificity values of miR-342 were 75.4% and 90%, respectively, with a cut-off value of 0.479. Our findings suggest that plasma miR-92a, miR-143 and miR-342 could be promising novel circulating biomarkers in clinical detection of AML.

Keywords: Leukemia, myeloid, acute, diagnosis, microRNAs.
Full-Text [PDF 577 kb]   (165 Downloads)    
Type of Study: Original Article | Subject: Biomarkers (diagnosis & treatment)
Received: 2016/12/30 | Accepted: 2017/02/27 | Published: 2017/05/31
Send email to the article author

Add your comments about this article
Your username or email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Elhamamsy A R, El Sharkawy M S, Zanaty A F, Mahrous M A, Ezzat Mohamed A, Abushaaban E A. Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia. Int J Mol Cell Med. 2017; 6 (2)
URL: http://ijmcmed.org/article-1-636-en.html
Volume 6, Number 2 (Int J Mol Cell Med 2017) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.048 seconds with 793 queries by yektaweb 3430